rSIFN-co in Combination With Total Neo-adjuvant Therapy in Subjects With Mid-low Locally Advanced Rectal Cancer

NCT07662278 · clinicaltrials.gov ↗

PHASE2

Phase

NOT_YET_RECRUITING

Status

90

Enrollment

INDUSTRY

Sponsor class

Conditions

Mid-low Locally Advanced Rectal Cancer

Interventions

DRUG: Recombinant Super-Compound Interferon (rSIFN-co)
DRUG: Total Neo-adjuvant therapy

Sponsor

Sichuan Huiyang Life Science and Technology Corporation